Zobrazeno 1 - 10
of 15
pro vyhledávání: ''
Publikováno v:
Molecular Cancer Research. 18:835-846
Through the use of an unbiased, genome-scale CRISPR modifier screen, we identified NF1 suppression as a mechanism of resistance to EGFR inhibition in NRAS/KRAS/BRAFV600-wild-type colorectal cancer cells. Reduced NF1 expression permitted sustained sig
Autor:
Akshata Udyavar, Junko Aimi, Ching-Wei Chang, Mark R. Lackner, Timothy R. Wilson, Heidi Savage, Jill M. Spoerke, Richard Bourgon, Anneleen Daemen, Joyce O'Shaughnessy
Publikováno v:
Molecular Cancer Research. 17:97-108
The identification of early breast cancer patients who may benefit from adjuvant chemotherapy has evolved to include assessment of clinicopathologic features such as tumor size and nodal status, as well as several gene-expression profiles for ER-posi
Autor:
Jae Hyung Park, Hyun Woo Park
Publikováno v:
Molecular Cancer Research. 18:B13-B13
The biologic significance and deregulation of the Hippo pathway during organ growth and tumorigenesis have received a surge of interest in the past decade. The Hippo pathway core kinases, MST1/2 and LATS1/2, are tumor suppressors that inhibit the onc
Publikováno v:
Molecular Cancer Research. 18:A37-A37
Lung cancer is the leading cause of cancer death worldwide, and it is estimated that 1.6 million deaths occur per year. Non-small cell lung cancer (NSCLC), mainly consisting of adenocarcinoma and squamous cell carcinoma, accounts for more than 80% of
Autor:
Stacy L. Littlechild, James J. Moresco, Thomas McFall, Ed Stites, Meron Mengistu, Andrey S. Shaw, Jolene K. Diedrich, Laura Sisk-Hackworth
Publikováno v:
Molecular Cancer Research. 18:B43-B43
Standard protocol to treat colorectal cancer (CRC) includes surgery, chemotherapy and radiotherapy as first-line treatment options. When applicable, targeting agents such as anti-EGFR therapies (i.e., cetuximab and panitumumab) have become important
Publikováno v:
Molecular Cancer Research. 16:B21-B21
Breast cancer is a heterogeneous disease, and stratification of patients is fundamental to the success of treatment modalities. Breast tumors deficient in BRCA1 are mostly associated with basal-like breast cancers, and targeted therapeutics for this
Publikováno v:
Molecular Cancer Research. 16:A30-A30
Luminal breast cancers account for ~75% of newly diagnosed cases and express estrogen receptor (ER) and a range of progesterone receptor (PR)-positive cells. Although adjuvant hormone therapies that target ER actions (e.g., tamoxifen or aromatase inh
Autor:
Satoshi Kano, Satoshi Fukuda, Tadasuke Tsukiyama, Shigetsugu Hatakeyama, Naoto Miyajima, Hiroyuki Maeda, Fumihiko Okumura
Publikováno v:
Molecular Cancer Research. 7:1553-1562
The ubiquitin-proteasome system has a crucial role in maintaining and regulating cellular homeostasis including carcinogenesis. UBE2Q2, also designated Ubci, is one of the ubiquitin-conjugating enzymes (E2), and it has been reported that mRNA of UBE2
Publikováno v:
Molecular Cancer Research. 14:IA08-IA08
Solid cancer cells commonly enter the blood and disseminate systemically but are highly inefficient at forming distant metastases for poorly understood reasons. We studied human melanomas that differed in their metastasis histories in patients and in
Autor:
Ivette J. Suarez-Arroyo, Luis A. Cubano, Geronimo Maldonado, Tiffany J. Rios-Fuller, Michelle M. Martínez-Montemayor, Mercedes Lacourt-Ventura
Publikováno v:
Molecular Cancer Research. 14:B20-B20
Inflammatory breast cancer (IBC) is a rare, and the most lethal and aggressive type of advanced breast cancer. Despite many efforts to increase IBC treatment efficacy, prognosis of this cancer is very grim. IBC cells and tissues overexpress epidermal